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Background: The influence of alcohol consumption on outcome in patients with peripheral artery disease (PAD) has not
been thoroughly studied.
Methods: Factores de Riesgo y ENfermedad Arterial (FRENA) is an ongoing, multicenter, observational registry of
consecutive stable outpatients with arterial disease. We compared the mortality rate and the incidence of subsequent
ischemic events in patients with PAD, according to their alcohol habits.
Results: As of August 2010, 1073 patients with PAD were recruited, of whom 863 (80%) had intermittent claudication
(Fontaine stage II), 102 (9.5%) had rest pain (Fontaine stage III), and 108 (10%) had ischemic skin lesions (Fontaine
stage IV). In all, 422 patients (39%) consumed alcohol during the study period. Over a mean follow-up of 13 months, 150
patients (14%) developed subsequent ischemic events (myocardial infarction 28, stroke 30, disabling claudication/critical
limb ischemia 100), and 70 patients (6.5%) died. The incidence of subsequent events was the same in both subgroups:
11.8 events per 100 patient-years (rate ratio: 1.00; 95% confidence interval [CI], 0.72-1.41), but the mortality rate was
significantly lower in alcohol consumers than in non-consumers: 2.78 vs 6.58 deaths per 100 patient-years (rate ratio:
0.42; 95% CI, 0.23-0.74; P  .002). This better outcome was consistently found in patients with Fontaine stages II and
III or IV, and persisted after multivariate adjustment (relative risk: 0.49; 95% CI, 0.28-0.88).
Conclusions: In patients with PAD, moderate alcohol consumption was associated with lower cardiovascular mortality and
overall mortality than abstention. These patients should be informed that low to moderate alcohol consumption may not
be harmful to their health. (J Vasc Surg 2011;54:1081-7.)
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oModerate alcohol consumption by apparently healthy
people is associated with lower cardiovascular morbidity
and mortality than in abstainers.1-8 A number of observa-
tional studies in patients with coronary or cerebrovascular
disease suggest that light to moderate alcohol consumption
may also be associated with a lower mortality,9-16 but there
is no available information on its influence on outcome in
patients with peripheral artery disease (PAD). Conse-
quently, guidelines in this area are based on experts’ con-
sensus rather than on clinical evidence.17-19
The Factores de Riesgo y ENfermedad Arterial
(FRENA) Registry was initiated inMarch 2003 to prospec-
tively record the current clinical management and outcome
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doi:10.1016/j.jvs.2011.03.285f patients with arterial disease in Spain. It is an ongoing,
ulticenter, observational registry of consecutive patients
esigned to gather and analyze data on treatment patterns
nd outcomes in stable outpatients with symptomatic isch-
mic disease of the heart, brain, and/or major peripheral
rteries. Data from this registry have been used to study the
nfluence of body weight, smoking habit, or glucose con-
rol on outcome.20-22 The aim of the current study was to
ompare the mortality rate and the incidence of subsequent
schemic events in patients with PAD, according to their
lcohol habit.
ATIENTS AND METHODS
Inclusion criteria. Participating hospitals in the
RENA registry prospectively enrolled consecutive outpa-
ients with symptomatic artery disease with at least one
ecent (3 months prior to enrollment) episode of coro-
ary artery disease (manifesting as angina or acute coronary
yndrome); cerebrovascular disease (manifesting as tran-
ient ischemic attack or ischemic stroke); or PAD (either
ntermittent claudication with an ankle-brachial index
0.9, or previous vascular intervention or limb amputation
or PAD). Patients were excluded if they would not be
vailable for follow-up, or if they were currently participat-
ng in a therapeutic clinical trial with a blinded therapy. All
atients provided written or oral consent prior to their
articipation in the registry, according to the requirements
f the ethics committee within each hospital.
Study design. For this study, only patients with PAD
ere considered. The Fontaine classification was used for
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try, patients were asked about the daily amount and type of
alcohol beverage. Then, at the 4-month visits, they were
asked again for any change in their habits. For the purpose
of this study, patients were categorized as alcohol consum-
ers or non-consumers. The primary outcome was overall
death during the study period. The secondary outcome was
the incidence of subsequent ischemic events (myocardial
infarction, ischemic stroke, or disabling claudication/criti-
cal limb ischemia).
Definitions. Myocardial infarction was defined as a
transient increase of creatine kinase-MB or troponin in
combination with ischemic symptoms and/or typical elec-
trocardiogram signs (development of pathologic Q-waves
or ST-segment elevation or depression). Ischemic stroke
was diagnosed if the patient had an appropriate clinical
event not resolving completely within 24 hours, and had a
brain computed tomography (CT) or magnetic resonance
imaging (MRI) that showed a compatible low-density le-
sion. Disabling claudication/critical limb ischemia was
considered in patients with intermittent claudication when
needing angioplasty, stenting, or surgery. In patients with
Fontaine stages III or IV, critical limb ischemia was consid-
ered when needing amputation. A patient was classified as
having diabetes when there was a clinical history of diabetes
or when they were taking insulin or oral antidiabetic agents.
Patients were classified as having hypertension when there
was a clinical history of hypertension or when they were
taking antihypertensive medications. Creatinine clearance
was calculated according to the Cockcroft and Gault for-
mula.24
Follow up. A detailed history was performed on all
patients at study entry (3 months after an acute ischemic
episode). Comorbid conditions were characterized, includ-
ing a history of coronary artery disease, cerebrovascular
disease or PAD, diabetes mellitus, hypertension, hyperlip-
idemia, chronic lung disease, chronic heart failure, cancer,
smoking status, and alcohol consumption. Then, physical
examination was performed comprising weight, height,
heart rate, and blood pressure on standard conditions, after
5 minutes of rest. An electrocardiogram was also recorded.
After the initial visit, patients were followed up at 4-month
intervals for at least 12 months. At these visits, any change
in medical history and data from physical examination was
recorded, with special attention to risk factors; laboratory
tests; lifestyle habits; the type, dose, and duration of treat-
ment received, and clinical outcome. Physicians were al-
lowed to use any and all appropriate medications, as dic-
tated by their usual clinical practice patterns.
Data collection. The attending physicians ensured
that eligible patients were consecutively enrolled. Data
were recorded on to a computer-based case report form at
each participating hospital and submitted to a centralized
coordinating center through a secure Web site. Patient
identities remain confidential because they were identified
by a unique number assigned by the study coordinating
center, which was responsible for all data management.
Data quality was regularly monitored and documentedable I. Clinical characteristics and treatment strategies
f 1073 patients with peripheral artery disease, according
o the consumption of alcohol
Alcohol
consumption No alcohol P value
atients, N 422 651
linical characteristics,
Mean age (years 
SD) 64  9.9 68  11 .001
Gender (males) 408 (97%) 491 (75%) .001
Body mass index
(mean  SD) 29  21 28  15 .591
Current smoking 174 (41%) 146 (22%) .001
nderlying diseases
Cancer 45 (11%) 57 (8.8%) .298
Hypertension 267 (63%) 454 (70%) .027
Diabetes 149 (35%) 331 (51%) .001
Chronic lung
disease 79 (19%) 129 (20%) .658
Chronic heart
failure 23 (5.5%) 74 (11%) .001
Prior coronary heart
disease 72 (18%) 165 (25%) .001
Prior
cerebrovascular
disease 36 (8.5%) 66 (10%) .381
linical presentation
Fontaine, stage II 351 (83%) 512 (79%) .068
Fontaine, stage III 44 (10%) 58 (8.9%) .408
Fontaine, stage IV 27 (6.4%) 81 (12%) .001
hysical examination
Atrial fibrillation 22 (5.2%) 59 (9.1%) .020
Mean SBP levels
(mm Hg) 142  16 141  17 .211
Mean DBP levels
(mm Hg) 75  9.0 74  9.6 .369
ean serum levels
CrCl (mL/min) 77  29 66  28 .001
Total cholesterol
(mg/100 mL) 186  34 180  37 .007
HDL-cholesterol
(mg/100 mL) 73  26 67  25 .001
LDL-cholesterol
(mg/100 mL) 110  31 107  30 .090
Triglycerides (mg/
100 mL) 152  241 145  98 .518
Glucose (mg/100
mL) 119  36 127  44 .002
rugs
Diuretics 170 (40%) 307 (47%) .027
Beta-blockers 67 (16%) 138 (21%) .030
ACE inhibitors 171 (41%) 269 (41%) .795
Angiotensin II
antagonists 128 (30%) 211 (32%) .474
Calcium antagonists 103 (24%) 193 (30%) .061
Antiplatelets 385 (91%) 583 (90%) .366
Anticoagulants 42 (10%) 110 (15%) .011
Statins 328 (77%) 482 (74%) .170
Insulin 47 (11%) 149 (23%) .001
Oral antidiabetics 132 (31%) 224 (34%) .288
CE, Angiotensin-conversive enzyme; CrCl, creatinine clearance; DBP,
iastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density
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Volume 54, Number 4 Garcia-Diaz et al 1083electronically to detect inconsistencies or errors, which are
resolved by the local coordinators. Data quality was also
monitored by periodic visits to participating hospitals by
contract research organizations that compared the medical
records with the data in the web. A data audit was per-
formed at periodic intervals.
Statistical analysis. Categorical variables were com-
pared using the 2 test (two-sided) and Fisher exact test
(two-sided). Odds ratios and corresponding 95% confi-
dence intervals (CI) were calculated, and a P value of.05
was considered to be statistically significant. Incidence rates
were calculated as cumulative incidence (events/100
patient-years) and compared using the rate ratio.25 Also, a
life table analysis was used to report follow-up events. The
association between consumption of alcohol and outcome
was assessed using the Cox proportional hazards regression
model, estimated by a forward step method. All variables
achieving a significance level of 0.1 in univariate analysis
were considered for inclusion in the logistic regression
model. Statistical analyses were conducted with SPSS for
Windows Release 17.0 (SPSS, Inc, Chicago, Ill).
RESULTS
As of August 2010, 1073 patients with PAD were
recruited in FRENA (29 refused enrollment), of whom 863
patients (80%) had intermittent claudication (Fontaine
stage II), 102 (9.5%) had pain at rest (Fontaine stage III),
and 108 (10%) had ischemic skin lesions (Fontaine stage
Table II. Incidence (per 100 patient-years) of subsequent
and consumption of alcohol
Alcohol consumption
All patients, N 422
Follow-up (years) 539.65
Myocardial infarction 1.31 (0.57-2.58)
Acute ischemic stroke 2.26 (1.23-3.85)
Disabling claudication/CLI 7.81 (5.65-10.5)
Any of the above 11.8 (9.08-15.2)
Death 2.78 (1.62-4.48)
Fontaine stage II, N 351
Follow-up (years) 444.71
Myocardial infarction 1.12 (0.41-2.49)
Acute ischemic stroke 1.80 (0.84-3.42)
Disabling claudication/CLI 5.85 (3.90-8.44)
Death 2.47 (1.30-4.30)
Fontaine stage III, N 44
Follow-up (years) 58.12
Myocardial infarction 1.72 (0.09-8.49)
Acute ischemic stroke 5.16 (1.31-14.0)
Disabling claudication/CLI 12.0 (5.31-23.8)
Death 3.44 (0.58-11.4)
Fontaine stage IV, N 27
Follow-up (years) 36.82
Myocardial infarction 2.72 (0.14-13.4)
Acute ischemic stroke 2.72 (0.14-13.4)
Disabling claudication/CLI 19.0 (8.32-37.6)
Death 5.43 (0.91-18.0)
CLI, Critical limb ischemia.IV). In all, 422 patients (39%) consumed alcohol during mhe study period (wine 312, beer 167, liquors 65). Of these,
51 (36%) consumed 20 g daily (ie, one can/bottle of
eer, glass of wine), 193 (46%) consumed 21 to 60 g/day
ie, 1000 mL of beer, 500 mL of wine), and 78 consumed
60 g/day.
Alcohol consumers were 4 years younger, more likely
ale and current smokers, and had hypertension, diabetes,
hronic heart failure, atrial fibrillation, or prior coronary
eart disease less often than non-consumers (Table I). They
resented more likely with Fontaine stage II, and less likely
ith Fontaine stage IV, they had higher mean serum levels
f creatinine clearance and cholesterol (total and high-
ensity lipoprotein cholesterol), and were less likely to
eceive diuretics, beta-blockers, anticoagulants, or insulin
han non-consumers.
Over a mean follow-up of 13 months (range, 3-46
onths), 150 patients (17%) developed subsequent isch-
mic events (myocardial infarction 28, stroke 30, disabling
laudication/critical limb ischemia 100), and 70 patients
6.5%) died. The incidence of subsequent ischemic events
as similar in alcohol consumers and non-consumers, but
he mortality rate was significantly lower in alcohol con-
umers: 2.78 versus 6.58 deaths per 100 patient-years; rate
atio: 0.42; 95% CI, 0.23 to 0.74 (P  .002). This lower
ortality was consistently found in patients with Fontaine
tages II and III or IV (Tables II and III). However, there
ere no significant differences in mortality according to
ither the amount of alcohol or the type of beverage: the
emic events or death, according to initial presentation
No alcohol
Rate ratio
(95% Confidence Interval) P value
651
836.41
1 (1.60-3.77) 0.52 (0.21-1.19) .129
6 (1.24-3.23) 1.20 (0.57-2.48) .795
3 (5.88-9.76) 1.02 (0.68-1.52) .906
8 (9.51-14.4) 1.00 (0.72-1.41) .971
8 (5.00-8.50) 0.42 (0.23-0.74) .002
512
673.15
3 (1.30-3.59) 0.50 (0.16-1.34) .183
9 (0.75-2.65) 1.21 (0.46-3.12) .686
6 (3.06-6.28) 1.31 (0.77-2.22) .314
1 (3.18-6.46) 0.54 (0.26-1.05) .070
58
65.52
3 (0.08-7.53) 1.13 (0.03-44.0) .940
5 (0.51-10.1) 1.69 (0.25-14.2) .596
7 (6.70-25.2) 0.88 (0.31-2.40) .805
6 (3.71-19.0) 0.38 (0.05-1.78) .238
81
97.75
1 (1.87-11.3) 0.53 (0.02-3.84) .626
1 (1.87-11.3) 0.53 (0.02-3.84) .626
5 (13.6-32.3) 0.88 (0.35-2.03) .807
4 (11.3-28.5) 0.30 (0.05-1.10) .074isch
2.5
2.0
7.6
11.
6.5
2.2
1.4
4.4
4.6
1.5
3.0
13.
9.1
5.1
5.1
21.
18.ortality rate was 2.60 (95% CI, 0.95-5.76) per 100 pa-
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1.17-5.31) in those consuming 21 to 60 g/day; and 2.69
(95% CI, 0.45-8.88) in those consuming60 g/day (P 
non significant [NS]). As for the type of beverage, the
mortality rate was 3.45 (95% CI, 1.97-5.66) per 100 pa-
tient-years in wine consumers; 2.41 (95% CI, 0.88-5.35) in
those consuming beer; and 4.97 (95% CI, 1.58-12.0) in
those consuming liquors (P  NS).
Patients who died were significantly older, weighed
less, and more likely to have comorbid diseases (cancer,
chronic heart failure, atrial fibrillation, or renal insuffi-
ciency) than those who survived. In addition, they pre-
sented more often with Fontaine stage III or IV, and were
more likely to have received diuretics or anticoagulants, but
less likely to have received statins (Table IV). On multivar-
iate analysis, alcohol consumption was independently asso-
ciated with a lower mortality (relative risk: 0.49; 95% CI,
0.27-0.88; P  .016), as depicted in Table V. Alcohol
consumers had a significantly lower incidence of cardiovas-
cular deaths (1.2% vs 4.2%; P .008) and a nonsignificantly
lower rate of non-cardiovascular deaths (2.4% vs 4.3%; P
.094), as shown in Table VI.
DISCUSSION
Alcohol consumption by apparently healthy people is
associated with lower cardiovascular morbidity and mortal-
ity than in abstainers,1-8 but its role among patients with
Table III. Life table analysis of subsequent events or deat
All patients
Time n
Alcohol
consumption n No al
Cumulative incidence of myocardial infarction ( SD)
6 Months 394 0.990  0.005 610 0.983 
1 Year 352 0.986  0.006 555 0.976 
2 Years 170 0.986  0.006 270 0.955 
3 Years 37 0.935  0.037 65 0.915 
P value .166
Cumulative incidence of ischemic stroke ( SD)
6 Months 394 0.989  0.005 610 0.988 
1 Year 352 0.975  0.008 555 0.979 
2 Years 168 0.950  0.016 271 0.962 
3 Years 35 0.950  0.016 55 0.962 
Cumulative incidence of disabling claudication/critical limb ische
6 Months 394 0.974  0.008 609 0.942 
1 Year 354 0.948  0.012 555 0.919 
2 Years 168 0.825  0.031 257 0.863 
3 Years 33 0.670  0.072 51 0.849 
P value .133
Cumulative mortality ( SD)
6 Months 397 0.987  0.006 620 0.964 
1 Year 357 0.967  0.010 570 0.942 
2 Years 172 0.953  0.013 281 0.859 
3 Years 37 0.921  0.034 58 0.790 
P value .020established arterial disease is less clear. Some observational rtudies in patients with a history of coronary heart dis-
ase,9-14 one study in patients with cerebrovascular dis-
ase,15 and a recent meta-analysis16 concluded that light to
oderate alcohol consumption was associated with a sig-
ificantly lower mortality. Three cohort studies performed
n a series of adults from The Netherlands,6 Greece,7 and
he United States,8 found that moderate alcohol consump-
ion was associated with a lower prevalence of PAD. Our
ata reveal that, in patients with PAD, alcohol consump-
ion is also associated with a significantly lower mortality,
nd this decreased mortality was mainly due to a decrease in
he incidence of cardiovascular deaths. This better outcome
as consistently found in patients presenting at different
tages of the disease (Fontaine stages II and III or IV), and
ersisted after multivariate adjustment. Thus, the findings
n this study complement existing knowledge regarding the
mpact of alcohol consumption on outcome in patients
ith arterial disease.
The 2006 Diet and Lifestyle Recommendations Scien-
ific Statement from the American Heart Association Nu-
rition Committee advises alcohol consumers to do so in
oderation.17 This means an average of one to two drinks
er day formen and one drink per day for women. Drinking
ore alcohol may increase alcoholism, high blood pressure,
besity, stroke, breast cancer, suicide, or accidents. Fur-
hermore, it is not possible to predict in which people
lcoholism will become a problem. Given these and other
cording to initial presentation
Fontaine stage II
n
Alcohol
consumption n No alcohol
5 326 0.991  0.005 482 0.981  0.006
6 290 0.987  0.007 442 0.976  0.007
3 139 0.987  0.007 219 0.958  0.014
3 30 0.945  0.042 45 0.944  0.019
.176
4 327 0.994  0.004 482 0.989  0.005
6 290 0.983  0.003 442 0.989  0.005
1 138 0.953  0.019 223 0.969  0.011
1 29 0.953  0.019 44 0.969  0.011
SD)
0 327 0.981  0.008 482 0.971  0.008
1 291 0.968  0.010 442 0.952  0.010
0 139 0.840  0.035 216 0.909  0.018
4 27 0.735  0.071 43 0.909  0.018
.572
8 328 0.987  0.006 488 0.975  0.007
0 293 0.973  0.009 450 0.959  0.009
3 141 0.957  0.015 226 0.901  0.024
0 31 0.917  0.042 47 0.814  0.047
.203h, ac
cohol
0.00
0.00
0.01
0.03
0.00
0.00
0.01
0.01
mia (
0.01
0.01
0.02
0.02
0.00
0.01
0.02
0.04isks, the American Heart Association cautions people not
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However, some concern has been raised regarding whether
it is advisable to encourage people who already drink to
maintain a lifestyle that includes moderate alcohol intake
rather than abstain completely.19,27,28
Over the past several decades, many studies have been
published about how drinking alcohol may be associated
with reduced mortality in some populations. Some mech-
anisms cited for the protective effect of moderate alcohol
consumption on outcome include its antiatherogenic role
in increasing the levels of high density lipoprotein choles-
terol,29 its hemostatic effects by decreasing platelet aggre-
gation30 and increasing fibrinolytic activity,31,32 and its
possible association with beneficial changes in insulin and
glucose metabolism.33-36 In our study, we failed to find any
difference in the mean levels of high-density lipoprotein
cholesterol according to alcohol consumption.
Some limitations of our research merit emphasis. First,
in our study, alcohol consumers were 4 years younger, had
fewer comorbidities, and less likely received diuretics, beta-
blockers, anticoagulants, or insulin than non-consumers.
Thus, the better outcome in this study may reflect pre-
existing, unrecognized diseases, even after making careful
exclusions. Hence, despite our efforts to control any bias
from underlying diseases, it is likely that we were unable to
eliminate such bias completely. Second, people who drink
in moderation may have a different lifestyle from people
who do not drink, and the apparent healthy effects associ-
ated with moderate alcohol consumption may be mostly
Table III. Continued.
Fontaine Stage III
n
Alcohol
consumption n No alcohol
41 0.976  0.024 52 1000  0.000
38 0.976  0.024 45 1000  0.000
19 0.976  0.024 20 1000  0.000
4 0.976  0.024 5 0.500  0.354
.283
41 0.949  0.035 52 0.981  0.019
38 0.922  0.043 46 0.958  0.029
18 0.922  0.043 20 0.958  0.029
4 0.922  0.043 5 0.958  0.029
41 0.923  0.043 53 0.862  0.048
39 0.841  0.060 46 0.862  0.048
17 0.777  0.083 19 0.723  0.101
4 0.777  0.083 5 0.723  0.101
.882
42 0.975  0.025 54 0.941  0.033
39 0.949  0,035 47 0.921  0.038
19 0.949  0,035 21 0.820  0.076
4 0.949  0,035 5 0.820  0.076
.385
SD, Standard deviation.due to favorable risk profiles in consumers. Third, any rnformation concerning alcohol consumption was based
xclusively on the patient’s report, with no objective con-
rmation. Fourth, the lack of information on length of
lcohol consumption prior to study entry may also limit our
onclusions since patients may modify their drinking habits
hortly after the diagnosis of arterial disease, usually reduc-
ng their alcohol intake. Finally, alcohol consumption is just
ne of several predictors of outcome in patients with PAD.
nfortunately, randomized controlled trials to assess the
nfluence of alcohol consumption in patients with arterial
isease are not feasible for several reasons, including ethical
onsiderations, so we have to rely on data from observa-
ional studies.
The study also has several strengths. To the best of our
nowledge, this is the first time the influence of alcohol
onsumption on outcome has been assessed in a series of
atients with PAD. We gathered data on important cardio-
ascular risk factors (such as smoking status, renal function,
nd cholesterol levels), continuation of alcohol consump-
ion during follow-up, and medication use. Moreover, we
id not exclude patients with underlying diseases or cancer.
The FRENA registry provides insights into the natural
istory of arterial disease with an unselected patient popu-
ation, in contrast to the rigorously controlled conditions of
andomized clinical studies. It can, therefore, help to iden-
ify factors associated with better or worse patient out-
omes, and provide feedback from real-world clinical situ-
tions, which may be valuable when designing new
Fontaine Stage IV
n
Alcohol
consumption n No alcohol
26 1.000  0.000 75 0.986  0.014
23 1.000  0.000 67 0.957  0.025
11 1.000  0.000 30 0.895  0.064
2 0.714  0.241 3 0.895  0.064
.282
26 1.000  0.000 74 0.987  0.013
23 0.960  0.039 66 0.924  0.033
11 0.960  0.039 28 0.924  0.033
2 0.960  0.039 6 0.924  0.033
25 0.962  0.038 73 0.807  0.047
23 0.878  0,066 66 0.735  0.054
11 0.721  0.114 22 0.637  0.084
2 0.000  0.000 6 0.539  0.115
.199
26 1.000  0.000 78 0.911  0.032
24 0.913  0.059 71 0.854  0.041
11 0.913  0.059 33 0.597  0.098
2 0.913  0.059 6 0.597  0.098
.148andomized clinical studies. Our data are hypothesis-
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situations.
In summary, our data reveal that moderate alcohol
consumption is associated with a lower mortality in
patients with PAD. This better outcome persisted after
adjusting for potential confounders, and was apparent at
different stages of the disease. Our current findings
suggest that alcohol consumers with PAD should con-
tinue to drink with moderation. However, translating
the results of observational cohort studies into clinical
Table IV. Predictors for mortality; univariate analysis
Death No death P value
Patients, N 70 1003
Clinical characteristics
Age 65 years 56 (80%) 538 (54%) .001
Gender (male) 58 (82%) 841 (84%) .828
Body mass index
27 21 (32%) 539 (55%) .001
Current smoking 10 (14%) 310 (31%) .003
Underlying disease
Cancer 18 (26%) 84 (8.4%) .001
Hypertension 47 (67%) 674 (67%) .992
Diabetes 37 (53%) 443 (44%) .157
Chronic lung disease 19 (27%) 189 (19%) .089
Chronic heart failure 11 (16%) 86 (8.6%) .044
Prior coronary heart
disease 19 (27%) 218 (22%) .292
Prior cerebrovascular
disease 13 (19%) 89 (8.9%) .007
Alcohol consumption
Yes 15 (21%) 407 (41%) .002
Clinical presentation
Fontaine, stage II 42 (60%) 821 (82%) .001
Fontaine, stages III–
IV 28 (40%) 182 (18%)
Physical examination
Atrial fibrillation 14 (20%) 67 (6.7%) .001
Mean laboratory levels
Creatinine clearance
60 mL/min 47 (70%) 364 (38%) .001
Total cholesterol
190 mg/dL 22 (33%) 366 (38%) .401
Low density
lipoprotein
cholesterol 100
mg/dL 33 (60%) 548 (60%) .949
Glucose 100 mg/
dL 51 (76%) 643 (67%) .145
Drugs
Diuretics 39 (56%) 438 (44%) .050
Beta-blockers 10 (14%) 195 (19%) .289
Angiotensin-
converting
enzyme inhibitors 26 (37%) 414 (41%) .497
Angiotensin II
antagonists 15 (21%) 324 (32%) .058
Calcium antagonists 18 (26%) 278 (28%) .717
Antiplatelets 62 (89%) 906 (90%) .632
Anticoagulants 17 (24%) 125 (13%) .005
Statins 37 (53%) 773 (77%) .001
Insulin 17 (24%) 179 (18%) .178
Oral antidiabetics 20 (29%) 336 (33%) .397recommendations is premature. SThe authors thank S & H Medical Science Service for
heir quality control, logistic, and administrative support,
nd Salvador Ortíz, Professor, Universidad Autónoma de
adrid, and Statistical Advisor, S & H Medical Science
ervice, for the statistical analysis of the data presented in
his paper.
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able V. Predictors for mortality; multivariate analysis
Death risk ratio
(95% confidence
interval) P value
nderlying diseases
Cancer 3.67 (2.11-6.39) .001
lcohol consumption
Yes 0.49 (0.27-0.88) .016
linical presentation
Fontaine, stage II 1 (Ref.)
Fontaine, stages III–IV 1.96 (1.18-3.27) .010
hysical examination
Atrial fibrillation 2.35 (1.25-4.43) .008
ean laboratory levels
Creatinine clearance
60 mL/min 2.34 (1.36-4.03) .002
rugs
Statins 0.43 (0.26-0.72) .003
able VI. Causes of death according to alcohol intake
Alcohol
consumption No alcohol
P
valuea
ll patients, N 422 651
ardiovascular death, N 5 (1.2%) 26 (4.2%) .008
Fatal critical limb ischemia 1 (0.2%) 9 (1.4%) .099
Fatal myocardial infarction 1 (0.2%) 5 (0.8%) .413
Heart failure 1 (0.2%) 1 (0.2%) 1.000
Sudden death 1 (0.2%) 3 (0.5%) 1.000
Ruptured aneurysm 1 (0.2%) 3 (0.5%) 1.000
Arrythmia 0 2 (0.3%) .522
Pulmonary embolism 0 2 (0.3%) .522
Fatal ischemic stroke 0 1 (0.2%) 1.000
on-cardiovascular death, N 10 (2.4%) 29 (4.3%) .094
Disseminated cancer 4 (0.9%) 11 (1.7%) .427
Infection 1 (0.2%) 5 (0.8%) .413
Bleeding 2 (0.5%) 1 (0.2%) .565
Chronic lung disease 0 2 (0.3%) .522
Unknown 2 (0.5%) 7 (1.1%) .495
Other 1 (0.2%) 3 (0.5%) 1.000
verall death 15 (3.6%) 55 (8.4%) .001
The P value has been calculated with Fisher’s exact test.tatistical analysis: MM
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